samedan logo
 
 
spacer
home > pmps > summer 2002 > new manufacturing technologies - from drug discovery to final product
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

New Manufacturing Technologies - From Drug Discovery to Final Product

Anyone working within the life sciences industries knows that it takes significant investments of time, human and monetary resources to bring a new drug from discovery to the finished goods state. During the last decade, average times for this process peaked at 15 years from inception to launch. During that time, all pharmaceutical firms worked aggressively to reduce the time to develop and market, and the late 1990s saw dramatic reductions (some as much as 40 per cent, but on average, reductions took the process from 15 years to around nine to 10 years).

The industry was once quite unique in its record of business success. With high growth rates, barriers to entry and profits, the pharmaceutical industry was recognised as one of the most successful business spaces in the world marketplace. Recent years, however, have seen the industry running up against a number of unforeseen changes in the manufacturing life cycle.

These changes have inhibited the development, marketing and eventual sales of new drugs, and have increased potential risks and the costs associated with them. Similar changes have taken place across the breadth of life sciences manufacturing, extending beyond pharmaceuticals to nutraceuticals/ dietary supplements, to clinical and biotech manufacturing, resulting in heightened risk, threats to agility, challenges in enterprise-wide collaboration, and impaired time to market.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Benjamin Bryant, Global Communications, at Honeywell Industry Solutions for Chemicals, Life Sciences and Consumer Goods Benjamin Bryant co-ordinates global communications for Honeywell's Chemicals, Life Sciences, and Consumer Goods business, his employer since 2000, when he represented the POMS business exclusively. Prior appointments include service as well-known radio and news presenter in Austin, Texas, and work for the United States Army & Exchange Service in merchandising and promotions.
Benjamin is a member of the Association of the United States Army and the Public Relations Society of America, where he serves on the 12-member executive board of the society's international section. He has attended the University of Texas and the business programme at the University of Phoenix.

spacer
Benjamin Bryant
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics closes a $40 million funding round led by Sofinnova Partners and Redmile Group

Cambridge, UK, 28 October 2021: Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million (circa 30 million) investment round. The round was led by Sofinnova Partners (Paris, France) and Redmile Group (San Francisco, USA) co-investing on equal terms.
More info >>

White Papers

Clinical Research in Spain

BioClever

This whitepaper is on clinical research in Spain, giving a general outline of the main characteristics of research in this country and an overview of the applicable regulations, along with the reasons why Spain is a good place to do research.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement